Phillip Md Et Al Frost Buys 100,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 100,000 shares of the firm’s stock in a transaction on Friday, November 22nd. The stock was bought at an average price of $1.59 per share, with a total value of $159,000.00. Following the purchase, the chief executive officer now directly owns 211,712,405 shares of the company’s stock, valued at $336,622,723.95. This represents a 0.05 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was purchased at an average cost of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost purchased 280,183 shares of OPKO Health stock. The shares were purchased at an average price of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Stock Performance

Shares of OPK opened at $1.58 on Monday. OPKO Health, Inc. has a 1 year low of $0.85 and a 1 year high of $1.75. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The company’s fifty day moving average is $1.52 and its two-hundred day moving average is $1.45. The stock has a market capitalization of $1.08 billion, a P/E ratio of -8.32 and a beta of 1.65.

Institutional Investors Weigh In On OPKO Health

Institutional investors have recently added to or reduced their stakes in the business. Lazard Asset Management LLC purchased a new position in OPKO Health in the first quarter valued at about $258,000. Price T Rowe Associates Inc. MD increased its stake in OPKO Health by 4.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company’s stock valued at $536,000 after purchasing an additional 17,671 shares in the last quarter. AWM Investment Company Inc. raised its holdings in OPKO Health by 18.2% during the first quarter. AWM Investment Company Inc. now owns 1,300,000 shares of the biotechnology company’s stock worth $1,560,000 after purchasing an additional 200,000 shares during the last quarter. Tidal Investments LLC purchased a new stake in OPKO Health during the first quarter worth $239,000. Finally, Comerica Bank grew its holdings in OPKO Health by 125.0% in the first quarter. Comerica Bank now owns 90,000 shares of the biotechnology company’s stock valued at $108,000 after purchasing an additional 50,000 shares during the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on OPK shares. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a report on Thursday, September 26th. Piper Sandler reiterated an “overweight” rating and set a $3.00 price target on shares of OPKO Health in a research note on Tuesday, September 17th. Finally, Barrington Research restated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Friday, November 8th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.